- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Company Appoints John Ryan, Ph.D., M.D., to serve as Senior Vice President, Chief Medical Officer, and Karen Roberts to serve as Senior Vice President, Finance and Administration
Cerulean Pharma Inc., a biopharmaceutical company focused on novel intelligently designed nanoparticle-based drugs, today announced the appointment of John Ryan, Ph.D., M.D., to serve as Senior Vice President, Chief Medical Officer and the appointment of Karen Roberts to serve as Senior Vice President, Finance and Administration. Both appointments are newly established roles that reflect Cerulean's growth and are effective immediately.
John Ryan has more than 20 years of experience in clinical research and development at AVEO Pharmaceuticals, Wyeth (formerly Genetics Institute), and Merck Research Laboratories. Most recently, Dr. Ryan served as Chief Medical Officer at AVEO Pharmaceuticals, Inc., where he built a clinical group for the development of oncology drugs. Prior to working in clinical development in the pharmaceutical industry, Dr. Ryan held Associate Professorships at both the University of Pennsylvania School of Medicine and Yale University School of Medicine. He holds a Ph.D. in Molecular Biophysics from Yale University and an M.D. from the University of California at San Diego.
Karen Roberts joins Cerulean after serving as Vice President, Finance and Administration at Elixir Pharmaceuticals, Inc., since Elixir's founding in 2001. At Elixir, Ms. Roberts was a core member of the executive management team and responsible for all aspects of accounting, finance and administration for that company. Prior to joining Elixir, Ms. Roberts held senior financial positions, where she was responsible for financial operations, at Frontline Group, Dyax Corporation and T Cell Sciences. Ms. Roberts was originally recruited into the life sciences field from Avery Dennison Corporation, where she held numerous financial positions of increasing responsibility. She holds a B.S. in Business Administration from Salem State College.
"We are tremendously excited about Dr. Ryan's transition from Acting Chief Medical Officer to Senior Vice President, Chief Medical Officer. His appointment to this position will assist us in aggressively advancing IT-101 in clinical development and in strategically progressing our growing pipeline into clinical development," said Dr. Oliver Fetzer, President and CEO of Cerulean.
"In addition, the appointment of Ms. Roberts, who has depth of experience in the life sciences industry, to the management team will provide Cerulean with key financial strategic guidance as we position the Company to become a leader in nanopharmaceuticals," said Dr. Fetzer.
About Cerulean Pharma
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from leadership companies and institutions. The company has been funded by leading investors Polaris Venture Partners, Venrock, Lux Capital, Bessemer Venture Partners, Alexandria Real Estate Equities, and William H. Rastetter. Cerulean is located in Cambridge, Massachusetts.
For more information, please click here
Cerulean Pharma Inc.
840 Memorial Drive, 5th Floor
Cambridge, MA 02139
Copyright © Cerulean PharmaIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Attosecond physics: Mapping electromagnetic waveforms July 25th, 2016
Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016